PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications
PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications
Last Updated: January 15, 2025
Research Use Only Disclaimer: Both PT-141 (Bremelanotide) and Melanotan II (MT-II) are sold exclusively for in vitro laboratory and preclinical research purposes. Neither compound is intended for human or veterinary use, consumption, or self-administration. All comparative information below is drawn from the peer-reviewed preclinical literature and is provided for scientific reference only.
When researchers are designing experiments that probe the melanocortin system, the choice between PT-141 and Melanotan II is not arbitrary. These compounds share a structural scaffold but differ in ways that directly affect which receptor subtypes they engage, how potently they activate signaling cascades in vitro, and what kinds of experimental questions they are best suited to answer. This article provides a detailed side-by-side comparison.
Structural Similarities and Differences
Both PT-141 and Melanotan II belong to the cyclic heptapeptide class of melanocortin analogs. They were developed from the same foundational research program at the University of Arizona, and both are derived structurally from alpha-melanocyte-stimulating hormone (alpha-MSH) with modifications designed to enhance stability and receptor affinity.
Melanotan II Structure
MT-II: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
PT-141 Structure
PT-141: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
The difference at first glance appears minor: the C-terminal amide (NH₂) in MT-II versus the free carboxyl (-OH) in PT-141. However, this modification is pharmacologically meaningful, as the C-terminal chemistry affects the overall charge distribution of the peptide and influences its interaction with the extracellular domains of melanocortin receptor subtypes.
Both compounds retain the core features introduced in early SAR work: - Norleucine (Nle) substitution for improved oxidative stability - D-Phenylalanine for enhanced receptor affinity and protease resistance - Cyclic lactam bridge between Asp and Lys side chains for conformational rigidity
Structural Comparison at a Glance
| Feature | Melanotan II (MT-II) | PT-141 (Bremelanotide) |
|---|---|---|
| C-terminal group | Amide (-NH₂) | Free carboxyl (-OH) |
| Cyclic lactam bridge | Yes | Yes |
| Norleucine at position 4 | Yes | Yes |
| D-Phe at position 7 | Yes | Yes |
| Molecular weight | ~1024 Da | ~1025 Da |
| CAS Number | 121062-08-6 | 189691-06-3 |
| Primary receptor targets | MC1R, MC3R, MC4R | MC3R, MC4R (MC1R lower) |
| Relative receptor selectivity | Broad (pan-agonist across MCRs) | More selective at MC3R/MC4R |
Receptor Pharmacology: Where the Research Diverges
The most important practical difference between MT-II and PT-141 for laboratory researchers is their receptor selectivity profile.
Melanotan II: Broad Melanocortin Receptor Agonism
MT-II is frequently described in the literature as a nonselective or pan-agonist at melanocortin receptors. Its binding affinity is high across MC1R, MC3R, and MC4R subtypes, and it also shows activity at MC5R in some assay systems. This broad receptor engagement has made MT-II an extremely useful pharmacological tool for experiments that seek to activate or block the melanocortin system globally, as a general probe for melanocortin biology.
The MC1R activity of MT-II is particularly notable. MC1R is the primary pigmentation receptor, expressed on melanocytes. In animal models, MT-II produces visible pigmentation effects through this pathway. This provides a visible biological readout in certain in vivo model systems, which is useful as a pharmacodynamic marker in whole-animal preclinical studies.
However, for researchers who want to study MC3R or MC4R pathways specifically without simultaneously engaging MC1R and the associated pigmentation biology, MT-II's broad agonism is a limitation. It becomes difficult to attribute observed biological effects to a specific receptor subtype when multiple subtypes are activated simultaneously.
PT-141: Relative Selectivity for MC3R and MC4R
PT-141's receptor selectivity profile differs from MT-II in ways that are useful for receptor-specific research designs. In published radioligand binding assays, PT-141 shows comparatively reduced activity at MC1R relative to MT-II, while maintaining high affinity at MC3R and MC4R.
This means that PT-141 is a more selective tool for probing the MC3R and MC4R receptor subtypes in vitro without the full confound of concurrent MC1R activation. For researchers studying autonomic or central nervous system-relevant signaling pathways through MC4R (the most CNS-expressed melanocortin receptor subtype), PT-141 provides a more pharmacologically precise experimental lever than MT-II.
Potency Comparison in Cell-Based Assays
Quantitative comparison of MT-II and PT-141 potency is receptor subtype and assay system dependent, but generalizations from the published preclinical literature include:
At MC1R: MT-II is substantially more potent than PT-141 in cAMP accumulation assays at this subtype. This is consistent with MT-II's known pan-agonist profile.
At MC4R: Both compounds show high affinity in radioligand binding at MC4R, with EC50 values in published in vitro cAMP assays in the low to sub-nanomolar range. Direct potency comparisons vary by assay system and cell line.
At MC3R: Both show activity, with published Ki values in the nanomolar range. Relative potency at MC3R may differ between assay systems.
Pharmacokinetic Properties in Preclinical Models
In preclinical animal studies, MT-II and PT-141 both show improved metabolic stability compared to native alpha-MSH, a direct result of their shared cyclic structure, Nle substitution, and D-Phe incorporation. Both are resistant to standard proteolytic degradation.
Differences in C-terminal chemistry (amide vs. carboxyl) may affect plasma half-life in rodent models, but this distinction is primarily relevant to in vivo research designs. For in vitro experiments, both compounds are stable in cell culture conditions for the duration of standard incubation periods.
Choosing Between PT-141 and MT-II: A Research Decision Framework
| Research Question | Preferred Compound | Rationale |
|---|---|---|
| Broad MCR system activation (pan-agonist needed) | MT-II | Higher activity across MC1R, MC3R, MC4R |
| MC4R-selective in vitro pharmacology | PT-141 | Lower MC1R engagement; cleaner MC4R data |
| MC3R-focused studies with reduced MC1R background | PT-141 | Relative selectivity benefit |
| Pigmentation-related MC1R research | MT-II | Higher MC1R potency |
| Comparative SAR studies on cyclic melanocortin scaffold | Both | Structural pair with single-variable difference |
| Reference standard for melanocortin receptor assays | Both | Widely cited in published literature |
Using MT-II and PT-141 Together in Research
Because MT-II and PT-II are structurally related but pharmacologically distinguishable, using both as paired tool compounds is a valid and common experimental strategy. By comparing effects at MC3R/MC4R systems activated by PT-141 versus the broader MCR activation produced by MT-II, researchers can draw inferences about the relative contribution of MC1R to observed biological outcomes in a given assay system.
For example, if a cellular response is observed with MT-II but not reproduced with PT-141 at equipotent MC4R concentrations, this suggests MC1R may be contributing to the MT-II response. This type of comparative pharmacology experiment represents one of the most rigorous applications of these two compounds in melanocortin receptor research.
Related Research Resources in This Cluster
- Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)
- History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications
- PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use
- PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research
- Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays: A Research Applications Guide
- PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes
Frequently Asked Questions
Q: What is the main structural difference between PT-141 and Melanotan II? The C-terminus: MT-II has an amide (-NH₂), PT-141 has a free carboxyl (-OH). Both are cyclic heptapeptides sharing core structural features from the same research lineage.
Q: Is PT-141 more selective than Melanotan II? Yes, at MC1R. PT-141 shows lower MC1R activity, making it more suitable for experiments focused on MC3R or MC4R signaling.
Q: Which is better for MC4R research? PT-141 is generally preferred due to reduced MC1R background confound, allowing cleaner MC4R-specific experimental interpretation.
Q: Can they be used together? Yes. Pairing them allows researchers to infer the contribution of MC1R to observed biological effects by comparing responses at equimolar concentrations.
Q: Do they have similar storage stability? Yes. Both share the same core stability features and follow similar storage recommendations.
Citations
Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930.
Wikberg JE, Mutulis F. "Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction." Nature Reviews Drug Discovery. 2008;7(4):307-323.
Hruby VJ, et al. "Design and synthesis of cyclic melanocortin analogs." Journal of Medicinal Chemistry. 1995;38:3454-3461.
Chhajlani V, Wikberg JE. "Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA." FEBS Letters. 1992;309(3):417-420.
Tao YX. "The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology." Endocrine Reviews. 2010;31(4):506-543.
Author: Palmetto Peptides Research Team
This article is for scientific and educational reference only. PT-141 and Melanotan II are research peptides sold exclusively for qualified laboratory use. Not intended for human or veterinary use. Researchers are responsible for all applicable regulatory compliance.
Part of the PT-141 Research Guide — Palmetto Peptides comprehensive research resource.